Hamilton Lane Advisors’s Pacira BioSciences PCRX Stock Holding History

Hamilton Lane Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-5,831	Closed	-$408K	–	63
2014 Q1	$408K	Buy	+5,831	New	+$397K	0.16%	54
2013 Q3	–	Sell	-12,022	Closed	-$349K	–	55
2013 Q2	$349K	Buy	+12,022	New	+$348K	0.2%	52

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Hamilton Lane Advisors's PCRX Position: Q2 2014 in Review

Hamilton Lane Advisors sold out of Pacira BioSciences (PCRX) in Q2 2014, closing a stake of 5,831 shares — an estimated $408K sold.

Hamilton Lane Advisors first reported a position in PCRX in Q2 2013 and held it in 2 quarters. The position peaked at $408K in Q1 2014. 191 funds tracked by Wall St. Rank hold PCRX as of Q2 2014.

Hamilton Lane Advisors reported no remaining Pacira BioSciences position as of Q2 2014 after selling out during the quarter.
Hamilton Lane Advisors sold 5,831 Pacira BioSciences shares in Q2 2014, an estimated $408K.
Hamilton Lane Advisors first reported a position in Pacira BioSciences in Q2 2013 and held it in 2 quarters.
Hamilton Lane Advisors's Pacira BioSciences position peaked at $408K in Q1 2014.
191 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2014.

Based on Hamilton Lane Advisors's 13F filing for Q2 2014, filed 2 Jul 2014.